Acorda Therapeutics Inc. (ACOR) announced Monday morning that data from a Phase 2 study of AMPYRA Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
Acorda Therapeutics gapped up sharply Monday and is now trading higher by 2.73 at $34.25. The stock has risen above a 2 1/2 week range and has set a new high for the year.
For comments and feedback: editorial@rttnews.com